Navigation Links
INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
Date:10/6/2010

Discovery of an Explanatory Model    

Company Awarded Patent # 7,617,171 B2

ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ -- Intercim, LLC, a global leader in manufacturing operation management (MOM) software, announced it has been awarded a patent called "Process for the iterative construction of an explanatory model".

This patented process is a key component of the Intercim Operations Intelligence technology and will help industrial manufacturers and life sciences researchers in two ways: unlike a statistics-based approach, it reuses existing information to optimize the length and cost of an experiment plan and it gives a quick and effective way to confirm the reliability of a discovery with only a few experiments.

This approach enables Pertinence Suite's users to get, much faster, a more reliable explanatory model even with limited data points available in a highly multi-dimensional non-euclidian space.

"This approach seems much easier to adopt than other standard Design of Experiment techniques, because we can analyze simultaneously the influence of many design parameters without statistical hypotheses. Thanks to the Interactive Experiment Planning of Process Rule Discovery(TM), we have reduced our need for physical experiments by 50% and sometimes more," says Dominique Veret, former Head of Development at Siemens Automotive Hydraulics, now Continental.

In the last 18 months, Intercim has received several additional patents which validate the uniqueness of Intercim's logic-based analytics for rule discovery and rule-based real-time predictions on complex systems and industrial processes. The announcement of this latest patent further demonstrates the unprecedented value proposition that Intercim offers to the market in terms of Operations Intelligence. John Todd, Intercim's CEO adds, "This patent confirms that Intercim truly offers a unique and high value-ad
'/>"/>

SOURCE Intercim
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
2. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
3. MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB"
4. MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
5. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
6. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
7. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
10. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
11. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received FDA ... adult men and women with androgenic alopecia (AGA) having ... IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... and under-deliver, FDA Clearance underscores the safety and efficacy ... than 80 million men and women who suffer with ...
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... dealing with certain matters, including the appointment of auditors, ... March 26, 2015 (the "Meeting") was adjourned, as previously ... at 11:00 a.m. ( Toronto time). ... from that previous disclosed. The Meeting will reconvene at ...
Breaking Biology Technology:Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... SAN DIEGO, Dec. 15, 2010 Ocera Therapeutics, ... studies evaluating the safety and pharmacokinetics of OCR-002 ... with liver cirrhosis.  OCR-002 recently received Orphan Drug ... States Food and Drug Administration for the treatment ...
... Dec. 14, 2010 Reportlinker.com announces that a ... catalogue: 2010 Membrane and Separation ... FOREWORD  ... as the myriad applications they are called upon ...
... Cylex Incorporated® today announced that the Centers ... tripled the reimbursement for ImmuKnow® , the immune ... cell-mediated immune response in populations undergoing immunosuppressive therapy ... in a time when the overall CMS clinical ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3Reportlinker Adds 2010 Membrane and Separation Technology Research Review 2Reportlinker Adds 2010 Membrane and Separation Technology Research Review 3Reportlinker Adds 2010 Membrane and Separation Technology Research Review 4Reportlinker Adds 2010 Membrane and Separation Technology Research Review 5Reportlinker Adds 2010 Membrane and Separation Technology Research Review 6Reportlinker Adds 2010 Membrane and Separation Technology Research Review 7Reimbursement Rate Nearly Tripled for Cylex's ImmuKnow® Assay 2
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... cause of cardiovascular disease, research from the Sahlgrenska Academy at ... body,s obesity hormones adiponectin - are also linked to ... skeleton is more than just bones, vertebrae and joints. In ... to our brain, our muscles and our fatty tissue. Stem ...
... Discovering new treatments and battling dangerous infections are the ... genetic disorder cystic fibrosis with projects funded by a ... support from a $110,000 grant from Hunt for a ... Institute, expand the relationship between the two organizations. Funding ...
... 2011) Policy decisions and poor management have substantially ... security, according to an article available today in the ... published by SAGE. The article calls into question media ... for the decline. , According to George Mason University ...
Cached Biology News:4 projects target cystic fibrosis with Hunt for a Cure funds 2Structure, not scientists to blame for Los Alamos failings 2Structure, not scientists to blame for Los Alamos failings 3
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Designed for use with any of the Agencourt kits in tube format....
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,405-4) or contact ... diam. 60 mm volume diam. ...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is a ... nucleus blue in color. The ... contrast to red fluorochromes such ... or R-Phycoerythrin. DAPI can be ...
Biology Products: